Professionals suggest that manufacturing capacity concerns in the cell and gene therapy space have lessened but a lack of adequate staffing is a growing fear. Conversation’s like this usually happen on the floor of exhibition centers. However, while face to face events are months away, BioProcess Insider has turned to LinkedIn to explore online discussions. Last week, vice president of Business Development at Cellares, Mark Flower posted “Has the industry reached the point that manufacturing capacity concerns have lessened or…

Samsung Biologics says virtual capabilities and supply chain management led to a successful year, despite the global pandemic. John Rim, the newly appointed president and CEO of Samsung Biologics, used a presentation at the JP Morgan Healthcare Conference to reveal that the company had signed $1.7 billion (€1.4billion) in contracts during 2021, a record for the company. Explaining how the company had managed to achieve this, Rim called attention to Samsung Biologics’ capacity for virtual exhibition halls and live-streaming tours.…